WVE WAVE Life Sciences

Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference

Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present virtually at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020 at 2:00 p.m. ET.

A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at . A replay of the presentation will be archived and available at that site for 90 days following the event.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit  and follow Wave on Twitter @WaveLifeSci.

Investor Contact:

Kate Rausch

617-949-4827

   

Media Contact:

Alicia Suter

617-949-4817

 

 

EN
26/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

Wave Life Sciences Ltd: 1 director

A director at Wave Life Sciences Ltd bought 8,772,496 shares at 6.227USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch